Form SC 13G/A Arcturus Therapeutics Filed by: BlackRock Inc.
- Futures climb as banking crisis fears abate
- Lululemon surges 15% on earnings, guidance beat; Stifel says shares still 'undervalued'
- UBS brings back Sergio Ermotti as CEO to oversee Credit Suisse takeover
- Micron Q2 results fall short of estimates amid weaker demand; bottom seen as deeper than expected
- European stocks get tech lift, UBS climbs on naming Ermotti as CEO
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Arcturus Therapeutics (ARCT) PT Lowered to $12 at Goldman Sachs
- Arcturus Therapeutics Announces Fourth Quarter 2022 Financial Update and Pipeline Progress
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!